Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

Part of Head and Neck Cancer

32 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Head and Neck Squamous Cell Carcinoma

77 trials tracked for Head and Neck Squamous Cell Carcinoma: 9 in phase 3 or 4 and 4 with published results. The most-cited published study has 804 citations.

77Trials tracked
9Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 1 Phase 3 8 Phase 2 60 Phase 1 6 Other / NA 2
  1. Phase 3 Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Completed · 804 cited
  2. Phase 3 A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) Completed · 78 cited
  3. Phase 3 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Completed · 64 cited
  4. Phase 3 Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer Completed · 18 cited
  5. Phase 4 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed
  6. Phase 3 Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer Completed
Show 44 more trials
  1. Phase 3 A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension Completed
  2. Phase 3 Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects Completed
  3. Phase 3 A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck Completed
  4. Phase 2 Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma Completed
  5. Phase 2 A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers Completed
  6. Phase 2 De-Escalation Therapy for Human Papillomavirus Negative Disease Completed
  7. Phase 2 Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. Completed
  8. Phase 2 A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) Completed
  9. Phase 2 HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma Completed
  10. Phase 2 A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients Completed
  11. Phase 2 Preoperative Treatment With Cetuximab and/or IMC-A12 Completed
  12. Phase 2 Expansion Trial for Axitinib In Head And Neck Cancer Completed
  13. Phase 2 Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients Completed
  14. Phase 2 A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study Completed
  15. Phase 2 Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer Completed
  16. Phase 2 Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Completed
  17. Phase 2 Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer Completed
  18. Phase 2 IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC Completed
  19. Phase 2 ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma Completed
  20. Phase 2 Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Completed
  21. Phase 2 Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer Completed
  22. Phase 2 Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma Completed
  23. Phase 2 Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer Completed
  24. Phase 2 Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer Completed
  25. Phase 2 Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Completed
  26. Phase 2 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Completed
  27. Phase 2 Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer Completed
  28. Phase 2 Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer Completed
  29. Phase 2 Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer Completed
  30. Phase 2 A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract Completed
  31. Phase 2 Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) Completed
  32. Phase 2 Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) Completed
  33. Phase 2 Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy Completed
  34. Phase 2 Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery Completed
  35. Phase 2 Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma Completed
  36. Phase 2 Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer Completed
  37. Phase 2 IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma Completed
  38. Phase 2 Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients Completed
  39. Phase 2 Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma Completed
  40. Phase 2 Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck Completed
  41. Phase 2 Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Completed
  42. Phase 2 Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Completed
  43. Phase 2 ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer Completed
  44. Phase 2 The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck Completed

Showing the 50 most-cited and recently-updated of 77 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Head and Neck Squamous Cell Carcinoma: what the trials found

Several immunotherapies have been evaluated for Head and Neck Squamous Cell Carcinoma. Nivolumab demonstrated a statistically significant improvement in Overall Survival (OS) compared to the control group (p=0.0101) 11. Additionally, Pembrolizumab was evaluated across multiple trials; one study reported a 2-year Progression-free Survival (PFS) of 75.5% 3, and other studies confirmed its use in various cohorts [7, 20].

Lenvatinib showed significant improvements in Objective Response Rate (ORR) (p=0.0000019) 12 and Progression Free Survival (PFS) (p=0.0000037) 15 compared to standard treatments, although the difference in Overall Survival was not statistically significant in these trials [12, 15].

Cetuximab has been studied both as a monotherapy and in combination with radiotherapy; while it showed some efficacy, results for Progression-free Survival (p=0.8878) and Overall Survival (p=0.8175) did not reach statistical significance 13. A separate trial evaluating Cetuximab plus concomitant boost radiotherapy was also conducted [17, 18].

Alternative radiation modalities include stereotactic body radiotherapy 10, while the use of MEDI4736 in combination with Tremelimumab or as monotherapy did not show statistically significant differences in Overall Survival compared to standard of care in specific PD-L1 high subgroups 14.

Recent results — preliminary, needs further review

  • Pembrolizumab showed a median Overall Survival of 14.9 months and a progression-free survival rate of 12% vs 7% in a small cohort 19.
  • Atezolizumab was associated with a 50.0% Pathologic Complete Response (pCR) rate compared to 16.7% in a small study, with no Grade 3 or higher immune-related adverse events reported 21.
  • Cisplatin treatment resulted in adverse event rates ranging from 21.9% to 38.5% across various categories 5.
  • Intensity modulated radiation therapy (IMRT) was associated with specific quality of life scores across several functional subscales 6.
  • Other recent investigations include paclitaxel/carboplatin 1, IO102-IO103 in combination with pembrolizumab 4, Nivolumab+Relatlimab 8, L-NMMA 9, and IPI-549 22.

For the clinician treating this condition

  • Nivolumab is associated with a statistically significant improvement in Overall Survival compared to standard treatments.
  • Lenvatinib provides significant improvements in Objective Response Rate (ORR) and Progression Free Survival (PFS), though it did not significantly impact Overall Survival in the studied cohorts.
  • Atezolizumab showed a high rate of Pathologic Complete Response (pCR) in a small cohort without reported high-grade immune-related adverse events.

AI synthesis of 16 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Post-operative ctDNA linked to worse survival in HPV-negative HNSCC, but estimate unstable
Oncology Meta-analysis
Post-operative ctDNA linked to worse survival in HPV-negative HNSCC, but estimate unstable ctDNA levels may signal cancer return in head and neck cancer
This meta-analysis examined post-operative ctDNA as a prognostic marker in HPV-negative head and neck squamous cell carcinoma. Detectable ct…
Detecting traces of cancer DNA in the blood after surgery may help identify patients at higher risk of cancer returning.
Frontiers Oct 16, 2026
Cisplatin Chemoradiotherapy for Elderly Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
ENT (Otolaryngology) RCT
Cisplatin Chemoradiotherapy for Elderly Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck New trial tests chemotherapy for elderly patients with head cancer
This trial protocol describes a study evaluating the use of weekly cisplatin in elderly patients with locally advanced squamous cell carcino…
A new trial aims to see if adding a specific chemotherapy drug helps elderly patients with advanced head and neck cancer.
Oct 11, 2026
Response-adapted surgery after neoadjuvant immune checkpoint inhibitors improves pathologic complete response in mucosal HNSCC
ENT (Otolaryngology) Meta-analysis
Response-adapted surgery after neoadjuvant immune checkpoint inhibitors improves pathologic complete response in mucosal HNSCC Response-Adapted Surgery May Help Preserve Organs in Head Cancer
This meta-analysis of patients with resectable mucosal head and neck squamous cell carcinoma (HNSCC) found that response-adapted surgery (RA…
A new approach to surgery after immunotherapy may help patients with head and neck cancer keep more of their natural tissue and function.
Oct 8, 2026
Weekly Cisplatin Regimen Shows Noninferiority to Standard Dosing in Head and Neck Cancer
Oncology RCT
Weekly Cisplatin Regimen Shows Noninferiority to Standard Dosing in Head and Neck Cancer Weekly cisplatin treatment shows promise for head and neck cancer
A randomized trial confirms that weekly cisplatin dosing achieves noninferiority in overall survival for high-risk squamous cell carcinoma p…
A new trial shows that giving chemotherapy weekly instead of every three weeks may offer a comparable survival rate for head and neck cancer…
Sep 20, 2026
Plant extracts like curcumin and resveratrol may inhibit HNSCC growth via specific signaling pathways
Drug Pipeline Sys. Review
Plant extracts like curcumin and resveratrol may inhibit HNSCC growth via specific signaling pathways Plant extracts may slow growth of head and neck cancer
This systematic review examines the effects of plant extracts, including resveratrol, curcumin, quercetin, and anthocyanins, on head and nec…
Certain plant compounds like curcumin and resveratrol show promise in stopping cancer cell growth and resisting chemotherapy in lab studies.
Frontiers Sep 13, 2026
Cetuximab-based regimens achieve 47% objective response rate in HNSCC after immune checkpoint inhibitor failure
ENT (Otolaryngology) Meta-analysis
Cetuximab-based regimens achieve 47% objective response rate in HNSCC after immune checkpoint inhibitor failure Cetuximab shows activity for head and neck cancer patients
This meta-analysis evaluates cetuximab-based regimens for patients with recurrent or metastatic head and neck squamous cell carcinoma follow…
New data shows cetuximab-based treatments provide meaningful results for head and neck cancer patients after other treatments fail.
Sep 8, 2026
Immune cell-based therapy shows no significant benefits for tumor response or survival in HNSCC trials
ENT (Otolaryngology) Meta-analysis
Immune cell-based therapy shows no significant benefits for tumor response or survival in HNSCC trials Immune cell therapy shows limited promise for head and neck cancer
This meta-analysis of 30 trials involving 953 patients evaluated immune cell-based therapy (ICT) for head and neck squamous cell carcinoma. …
New data on immune cell-based therapies for head and neck cancer shows mixed results and a need for more rigorous testing.
Sep 8, 2026
Perioperative and postoperative immunotherapy timing determines clinical outcomes in locally advanced head and neck squamous cell carcinoma
Allergy & Immunology Sys. Review
Perioperative and postoperative immunotherapy timing determines clinical outcomes in locally advanced head and neck squamous cell carcinoma Timing of immunotherapy affects outcomes for head and neck cancer
This narrative review examines the impact of immunotherapy sequencing on patients with locally advanced head and neck squamous cell carcinom…
The timing of immunotherapy treatment significantly changes how well it controls local and distant spread in head and neck cancer.
Frontiers Sep 4, 2026
ALC decline greater than 0.74x10^9/L independently predicts poorer OS and PFS in LA-HNSCC
Allergy & Immunology RCT
ALC decline greater than 0.74x10^9/L independently predicts poorer OS and PFS in LA-HNSCC Lymphocyte Drop During Radiation Tied to Worse Head and Neck Cancer Outcomes
This post-hoc analysis of a phase III trial involved 222 patients with locally advanced head and neck squamous cell carcinoma. The study fou…
A large drop in lymphocytes during radiation for head and neck cancer is linked to poorer survival. This finding may help personalize treatm…
Frontiers Aug 31, 2026
PD-1/PD-L1 inhibitors provide superior overall survival compared to chemotherapy or cetuximab in platinum-refractory HNSCC
Drug Pipeline Meta-analysis
PD-1/PD-L1 inhibitors provide superior overall survival compared to chemotherapy or cetuximab in platinum-refractory HNSCC Newer drugs show better survival for advanced head and neck cancer
This meta-analysis of 5 RCTs involving 1,700 patients found that PD-1/PD-L1 inhibitors resulted in superior overall survival (HR: 0.80) comp…
A review of clinical trials shows that certain immunotherapy drugs offer better survival rates and fewer severe side effects than traditiona…
Frontiers Aug 24, 2026
Pretreatment sarcopenia and low PNI are associated with worse survival in ICI-treated HNSCC
Geriatrics & Aging Meta-analysis
Pretreatment sarcopenia and low PNI are associated with worse survival in ICI-treated HNSCC Muscle Loss and Nutrition Linked to Survival in Head Cancer
This meta-analysis evaluates the prognostic impact of CT-based sarcopenia and nutritional indices on overall survival in patients with recur…
Low muscle mass and poor nutritional status are linked to worse survival outcomes for patients with advanced head and neck cancer.
Aug 4, 2026
Lenvatinib plus pembrolizumab did not improve overall survival compared to standard of care
Oncology RCT
Lenvatinib plus pembrolizumab did not improve overall survival compared to standard of care Trial shows lenvatinib and pembrolizumab do not improve survival
This Phase 2 randomized trial evaluated lenvatinib and pembrolizumab in 374 adults with recurrent or metastatic head and neck squamous cell …
A Phase 2 trial found that a combination of lenvatinib and pembrolizumab did not improve overall survival for patients with advanced head an…
Jul 27, 2026

Research across Head and Neck Cancer

Related studies from across the Head and Neck Cancer family.

YAP and TAZ Overexpression Predicts Worse Survival in Oral Squamous Cell Carcinoma
Oncology Meta-analysis
YAP and TAZ Overexpression Predicts Worse Survival in Oral Squamous Cell Carcinoma Hippo Pathway Markers Linked to Oral Cancer Survival Rates
This meta-analysis of 17 studies examined the prognostic value of Hippo pathway effectors YAP and TAZ in oral squamous cell carcinoma. Poole…
New data suggests that specific proteins in the Hippo pathway may help predict survival outcomes for patients with oral squamous cell carcin…
medRxiv Oct 13, 2026
EQ-5D Utility Values and Health Related Quality of Life
ENT (Otolaryngology) Meta-analysis
EQ-5D Utility Values and Health Related Quality of Life Understanding Quality of Life for Patients Living With Head and Neck Cancer
This meta-analysis quantifies EQ-5D utility scores for patients with head and neck cancer to inform survivorship care and cost-utility model…
New data helps doctors better understand how patients feel and function after being diagnosed with head and neck cancer.
Oct 8, 2026
Retropharyngeal lymph node involvement in oropharyngeal squamous cell carcinoma occurs in 11% to 16% of patients
ENT (Otolaryngology) Meta-analysis
Retropharyngeal lymph node involvement in oropharyngeal squamous cell carcinoma occurs in 11% to 16% of patients Retropharyngeal lymph node involvement impacts staging for throat cancer
This meta-analysis of 8,887 patients with oropharyngeal squamous cell carcinoma (OPSCC) identified a pooled prevalence of retropharyngeal ly…
New data shows that certain lymph nodes in the throat area are more likely to spread cancer in specific types of throat cancer cases.
Oct 8, 2026
HDAC inhibitors show 0.65 pooled favorable response rate in advanced head and neck cancer
ENT (Otolaryngology) Meta-analysis
HDAC inhibitors show 0.65 pooled favorable response rate in advanced head and neck cancer HDAC Inhibitors Show Promise for Advanced Head and Neck Cancer
This meta-analysis of single-arm trials evaluated HDAC inhibitor therapy for advanced head and neck cancer. The analysis found a pooled cumu…
A review of clinical trials shows that HDAC inhibitors may help patients with advanced head and neck cancer when used in combination with ot…
Oct 8, 2026
Low tumor volume reduction on CT and high FDG-PET SUVmax correlate with poorer outcomes in head and neck cancer
Radiology & Imaging Meta-analysis
Low tumor volume reduction on CT and high FDG-PET SUVmax correlate with poorer outcomes in head and neck cancer Tumor Imaging Metrics May Predict Outcomes for Head and Neck Cancer
This meta-analysis of 98 studies evaluated in-treatment tumor response measurements for patients with head and neck cancer undergoing radiot…
Specific imaging markers like tumor volume on CT and SUVmax on PET scans may help predict how well head and neck cancer treatment progresses…
Oct 6, 2026
Smoking history linked to worse survival in HPV-positive oropharyngeal cancer after TORS
Infectious Disease Meta-analysis
Smoking history linked to worse survival in HPV-positive oropharyngeal cancer after TORS Smoking History Linked to Worse Survival in Throat Cancer
In HPV-associated oropharyngeal cancer treated with transoral robotic surgery, smoking history was tied to worse overall survival, though re…
A history of smoking is linked to a higher risk of death for patients with certain types of throat cancer treated with robotic surgery.
Oct 4, 2026
Oral HPV reshapes mucosal microbial composition in a sex and population dependent manner
Infectious Disease Sys. Review
Oral HPV reshapes mucosal microbial composition in a sex and population dependent manner Oral and genital health linked to specific bacteria and HPV
This mini-review synthesizes evidence regarding the interaction between HPV infection and mucosal microbiota in oral, anorectal, and penile …
New research shows how specific bacteria and the HPV virus interact in the mouth and genital areas to influence cancer risk.
Frontiers Sep 24, 2026
Evaluating Dose Escalation to 60 Gy in Locally Advanced Esophageal Squamous Cell Carcinoma
Drug Pipeline RCT
Evaluating Dose Escalation to 60 Gy in Locally Advanced Esophageal Squamous Cell Carcinoma Trial shows higher radiation dose does not improve cancer survival
A Phase 3 trial compares 60 Gy versus 50 Gy of radiotherapy with concurrent chemotherapy for patients with unresectable esophageal squamous …
A large trial shows that increasing radiation doses for advanced esophageal cancer does not improve survival but may increase side effects.
Sep 20, 2026
SMMI framework provides a conceptual model for risk stratification in high-risk oral potentially malignant disorders
Oncology Meta-analysis
SMMI framework provides a conceptual model for risk stratification in high-risk oral potentially malignant disorders New Framework Helps Identify Risk of Oral Cancer Development
This evidence-ranked conceptual review proposes the spatial-microbial-metabolic-immune (SMMI) framework to study malignant transformation ri…
A new conceptual framework looks at how microbes and the immune system might help doctors better identify high risk for oral cancer developm…
Frontiers Sep 17, 2026
Distinct microbial taxa and functional pathways are associated with oral squamous cell carcinoma
Oncology Meta-analysis
Distinct microbial taxa and functional pathways are associated with oral squamous cell carcinoma Specific Bacteria Linked to Oral Squamous Cell Carcinoma
This meta-analysis identifies specific microbial taxa and functional pathways associated with oral squamous cell carcinoma. The findings hig…
Researchers identified specific types of bacteria and genetic pathways that are more common in people with oral squamous cell carcinoma.
Frontiers Sep 16, 2026
Long-read sequencing and assembly tools facilitate detection of complex viral integration structures in various cancers
Urology Sys. Review
Long-read sequencing and assembly tools facilitate detection of complex viral integration structures in various cancers New Guide Maps Best Tools to Find HPV Integration
This systematic review evaluates the use of long-read sequencing technologies and assembly tools for identifying complex viral integration s…
A new review compares DNA sequencing tools for spotting how HPV inserts itself into cancer cells, a key step in several cancers.
Frontiers Sep 16, 2026
Egg consumption associated with reduced glioma risk in Eastern populations and increased head and neck cancer risk
ENT (Otolaryngology) Meta-analysis
Egg consumption associated with reduced glioma risk in Eastern populations and increased head and neck cancer risk Egg consumption shows mixed links to glioma and head and neck cancer
This meta-analysis of observational studies involving 1,274,437 participants found that egg consumption was associated with a reduced risk o…
New data shows a link between egg consumption and lower glioma risk in some groups, but a potential link to higher head and neck cancer risk…
Sep 12, 2026

Questions about Head and Neck Squamous Cell Carcinoma

What is the objective response rate for becotatug vedotin in recurrent head and neck cancer?

Becotatug vedotin showed a 20.9% objective response rate in recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.

Full answer →
Does reducing radiotherapy doses lower toxicity in head and neck squamous cell carcinoma?

Yes, reducing radiotherapy doses through margin reduction, adaptive planning, or proton therapy can lower acute and late toxicity in head and neck squamous cell carcinoma, though clinical benefits may be modest in unselected patients.

Full answer →
What are the risks of HPV-associated head and neck squamous cell carcinoma?

HPV-associated head and neck squamous cell carcinoma risks include persistent HPV infection (especially HPV16), distinct metabolic changes, and epigenetic dysregulation, but these tumors often have a better prognosis than HPV-negative cancers.

Full answer →
How do therapeutic cancer vaccines work for head and neck squamous cell carcinoma?

Therapeutic cancer vaccines train the immune system to recognize and attack HNSCC cells by targeting tumor-specific antigens, but achieving durable responses remains challenging.

Full answer →

All Head and Neck Squamous Cell Carcinoma Articles